BioWorld

April 23, 2010

View Archived Issues

Transient Receptor Potential Channels Keep Branching Out

Aragon Raises $22M to Move 2 Cancer Drugs Into the Clinic

Earnings Roundup

Stock Movers

Clinic Roundup

Other News To Note

After Mixed Phase III, Alimera Prices $72M IPO Below Range

Four months after delivering mixed Phase III data on diabetic macular edema drug Iluvien, Alimera Sciences Inc. raised $72.1 million in its initial public offering. (BioWorld Today) Read More

Amgen Boasts Solid Quarter; Prolia Launch on the Horizon

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...